parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (786 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13305

GRID1 in dopamine neurons, braak-0.11 (p 0.773) → -0.80 (p 0.009)receipt 13314
GRID1 in oligodendrocytes, braak-0.58 (p 0.102) → -0.17 (p 0.668)receipt 13313

receipt 13314: GRID1 in dopamine neurons, braak

power: full sample -0.39 (p 0.111, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.40 (p 0.101, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.037, n 18). not the mix.
skeptic: leave-one-out range -0.54 to -0.32, sign flips 0; without severely affected donors -0.39 (p 0.111, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRID1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 13313: GRID1 in oligodendrocytes, braak

power: full sample -0.38 (p 0.120, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.43 (p 0.079, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.43 (p 0.079, n 18). could be the mix.
skeptic: leave-one-out range -0.55 to -0.31, sign flips 0; without severely affected donors -0.38 (p 0.120, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GRID1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts